FAK-targeting PROTAC demonstrates enhanced antitumor activity against KRAS mutant non-small cell lung cancer
Author:
Publisher
Elsevier BV
Subject
Cell Biology
Reference29 articles.
1. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs;Kris;J. Am. Med. Assoc.,2014
2. Drugging an undruggable pocket on KRAS;Kessler;Proc. Natl. Acad. Sci. U. S. A,2019
3. Oct 25). Understanding and targeting resistance mechanisms in NSCLC;Rotow;Nat. Rev. Cancer,2017
4. Jan 25). Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor;Janes;Cell,2018
5. Direct Ras G12C inhibitors: crossing the rubicon;Lindsay;Br. J. Cancer,2019
Cited by 12 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. FAK inhibitors in cancer, a patent review – an update on progress;Expert Opinion on Therapeutic Patents;2024-07-02
2. Research progress on small molecule inhibitors targeting KRAS G12C with acrylamide structure and the strategies for solving KRAS inhibitor resistance;Bioorganic & Medicinal Chemistry;2024-02
3. Proteolysis targeting chimeras in non-small cell lung cancer;Cancer Treatment Reviews;2023-06
4. PROTAC’ing oncoproteins: targeted protein degradation for cancer therapy;Molecular Cancer;2023-03-30
5. PROTAC therapy as a new targeted therapy for lung cancer;Molecular Therapy;2023-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3